Inhibitory effect of cycloSaligenyl-nucleoside monophosphates (cycloSal-NMP) of acyclic nucleoside analogues on HSV-1 and EBV

Antiviral Research

Volumn 45, Issue 1, 2000, Pages 69-77

  Meerbach, Astrid ^a   Klöcking, Renate ^a   Meier, Chris ^b   Lomp, Andreas ^b   Helbig, Björn ^a   Wutzler, Peter ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Anti EBV; Anti HSV 1; Pro nucleotides

Indexed keywords

ACICLOVIR; ACICLOVIR DERIVATIVE; ACYCLIC NUCLEOSIDE; ANTIVIRUS AGENT; CIDOFOVIR; NUCLEOSIDE DERIVATIVE; PENCICLOVIR;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; EPSTEIN BARR VIRUS; HERPES SIMPLEX VIRUS 1; IMMUNOFLUORESCENCE; NONHUMAN; PRIORITY JOURNAL; VERO CELL;

ACYCLOVIR; ANIMALS; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CAPSID PROTEINS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; DNA, VIRAL; HERPESVIRUS 1, HUMAN; HERPESVIRUS 4, HUMAN; THYMIDINE KINASE; VERO CELLS; VIRUS REPLICATION;

HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 4; MIRIDAE;

EID: 0342948879     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(99)00076-5     Document Type: Article

References (48)

1. Alrabiah F.A., Sacks S.L. New antiherpesvirus agents. Their targets and therapeutic potential. Drugs. 52:1996;17-32.
2. Anagnostopoulos I., Hummel M. Epstein-Barr virus in tumours. Histo-Pathol. 29:1996;297-315.
3. Andersson J., Britton S., Ernberg I., Andersson U., Henle W., Sköldenberg B., Tisell A. Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study. J. Infect. Dis. 153:1986;283-290.
4. Bacon T.H., Boyd M. Activity of penciclovir against Epstein-Barr virus. Antimicrob. Agents Chemother. 39:1995;1599-1602.
5. Benda R., Petrovic S., Rychterova V. Transmission of herpesvirus along the trigeminal nerve in rabbits. Acta Virol. 16:1972;459-465.
6. Boyd M.R., Bacon T.H., Sutton D., Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)-guanine (BRL39123) in cell culture. Antimicrob. Agents Chemother. 31:1987;1238-1242.
7. Brandwein M., Nuovo G., Ramer M., Orlowski W., Miller L. Epstein-Barr virus reactivation in hairy leukoplakia. Mod. Pathol. 9:1996;298-303.
8. Burkitt D.B. Sarcoma involving jaws in African children. Br. J. Surg. 46:1958;218-223.
9. Cao S., Cox K., Esquivel C.O., Berquist W., Concepcion W., Ojogho O., Monge H., Krams S., Martinez O., So S. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein-Barr virus infection in children following liver transplantation. Transplantation. 66:1998;851-856.
10. Chatis P.A., Crumpacker C.S. Resistance of herpesvirus to antiviral drugs. Antimicrob. Agents Chemother. 36:1992;1589-1595.
11. Colby B.M., Shaw J.E., Elion G.B., Pagano J.S. Effect of acyclovir [9-(2-hydroxyethoxymethyl)-guanine] on Epstein-Barr virus DNA replication. J. Virol. 34:1980;560-568.
12. De Clercq E. Trends in the development of new antiviral agents for the chemotherapy of infections caused by herpesviruses and retroviruses. Rev. Med. Virol. 5:1995;149-164.
13. Dubbs D.R., Kit S. Mutant strains of herpes simplex deficient in thymidine kinase-inducing activity. Virology. 22:1964;493-502.
14. Elion G.B., Furman P.A., Fyfe J.A., de Miranda P., Beauchamp L., Schaeffer H.J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc. Natl. Acad. Sci. USA. 74:1977;5716-5720.
15. Emanuel J.R. Simple and efficient system for synthesis of non-radioactive nucleic acid hybridization probes using PCR. Nucleic Acids Res. 19:1991;2790.
16. Englund J.A., Zimmermann M.E., Swierkosz E.M., Goodman J.L., Scholl D.R., Balfour H.H. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann. Int. Med. 112:1990;416-422.
17. Epstein, M.A., Achong, B.G., Barr, Y.M., 1964. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet I, 702-703.
18. Francois P. I.D.U. in ophthalmology. Annee. Ther. Clin. Ophthalmol. 14:1963;261-270.
19. Glaser S.L., Lin R.J., Stewart S.L., Ambinder R.F., Jarrett R.F., Brousset P., Pallesen G., Gulley M.L., Khan G., O'Grady J., Hummel M., Preciado M.V., Knecht H., Chan J.K.C., Claviez A. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int. J. Cancer. 70:1997;375-382.
20. Greenspan D., De Souza Y.G., Conant M.A., Hollander H., Chapman S.K., Lennette E.T., Petersen V., Greenspan J.S. Efficacy of desciclovir in the treatment of Epstein-Barr virus infection in oral hairy leukoplakia. J. Aquired Immune Deficiency Syndromes. 3:1990;571-578.
21. Klöcking R., Schacke M., Wutzler P. Primärscreening antiherpetischer Verbindungen mit EZ4U. Chemother. J. 4:1995;141-147.
22. Kost R.G., Hill E.L., Tigges M., Straus S.E. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent host. New Engl. J. Med. 329:1993;1777-1782.
23. Kuo P.C., Dafoe D.C., Alfrey E.J., Sibley R.K., Scandling J.D. Posttransplant lymphoproliferative disorders and Epstein-Barr virus prophylaxis. Transplantation. 59:1995;135-138.
24. Leoncini L., Vindigni C., Megha T., Funto I., Pacenti L., Musaro M., Renieri A., Seri M., Anagnostopoulos J., Tosi P. Epstein-Barr virus and gastric cancer: data and unanswered questions. Int. J. Cancer. 53:1993;898-901.
25. Lin J.-C., Shaw J.E., Smith M.C., Pagano J.S. Effect of 12-O-Tetra-decanoylphorbol-13-acetate on the replication of Epstein-Barr Virus. I. Characterization of viral DNA. Virology. 99:1979;183-187.
26. Lin J.-C., Smith M.C., Pagano J.S. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus. J. Virol. 50:1984;50-55.
27. Lin J.-C., De Clercq E., Pagano J.S. Inhibitory effects of acyclic nucleoside phosphonate analogs, including (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)-cytosine, on Epstein-Barr virus replication. Antimicrob. Agents Chemother. 35:1991;2440-2443.
28. Meerbach A., Holy A., Wutzler P., De Clercq E., Neyts J. Inhibitory effects of novel nucleoside and nucleotide analogues on Epstein-Barr virus replication. Antiviral Chem. Chemother. 9:1998;275-282.
29. Meier C., Knispel T., Lorey M., Balzarini J. CycloSal-pro-nucleotides: the design and biological valuation of a new class of lipophilic nucleotide prodrugs. Int. Antiviral News. 5:1997;183-185.
30. Meier, C., 1998. Pro-nucleotides-recent advances in the design of efficient tools for the delivery of biologically active nucleoside monophosphates. Synlett, 233-242.
31. Meier C., Habel L., Haller-Meier F., Lomp A., Herderich M., Klöcking R., Meerbach A., Wutzler P. Chemistry and anti-HSV-1 evaluation of cycloSal-nucleotides (cycloSal-NMP) of acyclic nucleoside analogues. Antiviral Chem. Chemother. 9:1998;389-402.
32. Meijer C.J.L.M., Jiwa N.M., Dukers D.F., Oudejans J.J., De Bruin P.C., Walboomers J.M.M., Van den Brule A.J.C. Epstein-Barr virus and human T-cell lymphomas. Sem. Cancer Biol. 7:1996;191-196.
33. Niedobitek G. The role of Epstein-Barr virus in the pathogenesis of Hodgkin's disease. Ann. Oncol. Suppl. 7. 4:1996;S11-S17.
34. Nyquist A.C., Rotbart H.A., Cotton M., Robinson C., Weinberg A., Hayward A.R. et al. Acyclovir-resistant neonatal herpes simplex virus infection of the larynx. J. Ped. 124:1994;967-971.
35. Okano M., Matsumoto S., Osato T., Sakiyama Y., Thiele G.M., Purtilo D.T. Severe chronic active Epstein-Barr virus infection syndrome. Clin. Microbiol. Rev. 4:1991;129-135.
36. Osato T., Imai S. Epstein-Barr virus and gastric carcinoma. Sem. Cancer Biol. 7:1996;175-182.
37. Pagano, J.S., Sixbey, J.W., Lin, J.-C., 1983. Acyclovir and Epstein-Barr virus infection. J. Antimicrob. Chemother. 12, Suppl. B, 113-121.
38. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyter J., De Clercq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods. 20:1988;309-321.
39. Pavan-Langston D. Use of vidarabine in ophthalmology: a review. Ann. Ophthalmol. 9:1977;835-839.
40. Rawls, W.E., 1973. Herpes simplex virus. In: Kaplan, A.S. (Ed.), The herpesviruses. Academic Press, New York, 291-325.
41. Reyes, M., Graber, J.M., Weatherall, N., Hodges-Savola, C., Reeves, W.C. and the Task Force on herpesvirus resistance, 1998. Acyclovir-resistant herpes simplex virus: Preliminary results from a national surveillance system. Antiviral Res. 37, A44/16.
42. Savage P., Waxman J. Post-transplantation lymphoproliferative disease. Quart. J. Med. 90:1997;497-503.
43. Shibata D., Weiss L.M., Hernandez A.M., Nathwani B.N., Bernstein L., Levine A.M. Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. Blood. 81:1993;2102-2109.
44. Su B.I.-J., Hsieh H.-C., Lin K.-H., Uen W.-C., Kao C.-L., Chen C.-J., Cheng A.-L., Kadin M.E., Chen J.-Y. Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: a clinicopathologic and molecular analysis. Blood. 77:1991;799-808.
45. Van der Horst C., Joncas J., Ahronheim G., Gustafson N., Stein G., Gurwith M., Fleisher G., Sullivan J., Sixbey J., Poland S., Fryer J., Champney K., Schooley R., Sumaya C., Pagano J.S. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. J. Infect. Dis. 164:1991;788-792.
46. Wagstaff A., Faulds D., Goa K.L. Aciclovir: a reappraisal of ist antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 47:1994;153-205.
47. Wutzler P. Antiviral therapy of herpes simplex and varicella-zoster virus infections. Intervirology. 40:1997;343-356.
48. zur Hausen H., Schulte-Holthausen H., Klein G., Henle W., Henle G., Clifford P., Santesson L. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature. 228:1970;1056-1058.